Pharmacokinetic and safety profile of tofacitinib in children with polyarticular course juvenile idiopathic arthritis: results of a phase 1, open-label, multicenter study

BACKGROUND: Juvenile idiopathic arthritis (JIA) is the most common pediatric rheumatic disease and a leading cause of childhood disability. The objective of this study was to characterize the PK, safety, and taste acceptability of tofacitinib in patients with JIA. METHODS: This Phase 1, open-label,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruperto, Nicolino, Brunner, Hermine I., Zuber, Zbigniew, Tzaribachev, Nikolay, Kingsbury, Daniel J., Foeldvari, Ivan, Horneff, Gerd, Smolewska, Elzbieta, Vehe, Richard K., Hazra, Anasuya, Wang, Rong, Mebus, Charles A., Alvey, Christine, Lamba, Manisha, Krishnaswami, Sriram, Stock, Thomas C., Wang, Min, Suehiro, Ricardo, Martini, Alberto, Lovell, Daniel J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745974/
https://www.ncbi.nlm.nih.gov/pubmed/29282090
http://dx.doi.org/10.1186/s12969-017-0212-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5745974/
https://www.ncbi.nlm.nih.gov/pubmed/29282090
http://dx.doi.org/10.1186/s12969-017-0212-y

Ejemplares similares